Acquisition - December 10, 2025
LINK Medical transfers selected operations previously part of SDS Life Science
LINK Medical has announced the transfer of specific business areas from SDS Life Science (an affiliate of Cytel), namely the Drug Development Consulting and Clinical Project Management/Medical Writing units.
Clinical Trials - December 10, 2025
AnaCardio reports new Phase 2a results
AnaCardio has announced topline results from the Phase 2a portion of its GOAL-HF1 clinical study program evaluating AC01 in patients with heart failure and reduced ejection fraction (HFrEF).
In a new job - December 10, 2025
She is the new CFO of BICO Group
BICO Group has announced the appointment of Ewa Linsäter as Chief Financial Officer.
Global report - December 9, 2025
Pfizer enters into agreement with YaoPharma
Pfizer has entered into an exclusive global collaboration and license agreement with YaoPharma, a subsidiary of Shanghai Fosun Pharmaceutical for the development, manufacturing and commercialization of YP05002, a small molecule glucagon-like peptide 1 (GLP-1) receptor agonist currently in Phase 1 development for chronic weight management.
MedTech Business - December 9, 2025
CellaVision receives CE marking
CellaVision has announced that its new CellaVision Bone Marrow Aspirate (BMA) Application has received CE marking approval as a Class C product under the European Union In Vitro Diagnostic Regulation (EU IVDR).
Biotech Business - December 9, 2025
Leqembi included in China’s commercial insurance innovative drug list
BioArctic’s partner Eisai has announced that Leqembi (lecanemab), has been included in the “Commercial Insurance Innovative Drug List”, recently introduced by the National Healthcare Security Administration (NHSA) of China.
